Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Suspended 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Sarcoma 3

Conditions

Sarcoma 3Sarcoma, Ewing 1Osteosarcoma 1Neoplasms 1Bone Neoplasms 1

Interventions

Doxorubicin 142Ifosfamide 85Radiotherapy 82Cyclophosphamide 72Gemcitabine 63Filgrastim 54pembrolizumab 43pazopanib 40Etoposide 39Docetaxel 39Vincristine 37Trabectedin 37Cisplatin 35Nivolumab 32Magnetic Resonance Spectroscopy 26Irinotecan 26Carboplatin 25Temozolomide 23Surgical Procedures, Operative 23Radiation 22Ipilimumab 22Bevacizumab 20Blood Specimen Collection 19Granulocyte Colony-Stimulating Factor 18Biopsy 18eribulin 17Sirolimus 17Mesna 17Melphalan 17Dactinomycin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Sarcoma × HMPL-013 × Sarcoma × Clear all
NCT05941325 2026-05-14

A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma

Shanghai 6th People's Hospital

Phase 2 Suspended
20 enrolled
Sarcoma

Sarcoma

NCT06202599 2024-01-17

Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance

Peking University People's Hospital

Completed
124 enrolled
Sarcoma

Bone Neoplasms, Neoplasms, Sarcoma, Sarcoma, Ewing, Osteosarcoma

NCT05142631 2022-03-02

Fruquintinib in the Treatment of Soft Tissue Sarcoma

Fudan University

Phase 2 Unknown
31 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡